Evidence map›Paper›PMID 39966122›Full record

ArticleAnnals of hematology2025

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.

Shunjie Yu, Sen Yang, Lijuan Hu, Wenbing Duan, Ting Zhao, Yazhen Qin, Yazhe Wang, Yueyun Lai, Hongxia Shi, Feifei Tang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Advancements in diagnosis and treatments of acute leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cancers · 2025
    Article
  7. Cancers · 2025
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Shunjie Yu *Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Sen Yang *Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Lijuan HuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Wenbing DuanBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Ting ZhaoBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Yazhen QinBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Yazhe WangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Yueyun LaiBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Hongxia ShiBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Feifei TangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Yuqian SunBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Jinsong JiaBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Jing WangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Shengye LuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Qiang FuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Hao JiangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Lanping XuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Yu WangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Xiaohui ZhangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Xiaojun HuangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China.
Qian JiangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, No. 11 Xizhimen South St, Beijing, China. jiangqian@medmail.com.cn.

Funding

National Natural Science Foundation of China 81970140
6 · The paper itself

Abstract

Research on the comprehensive integration of clinical and genomic characteristics in patients with core binding factor acute myeloid leukemia (CBF-AML) is limited. Clinical and genomic data from consecutive patients with CBF-AML were reviewed. A Cox regression model was used to identify the variables associated with event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). A total of 346 CBF-AML patients (211 with RUNX1::RUNX1T1 and 135 with CBFB::MYH11) were included in this study. In the RUNX1::RUNX1T1 cohort, multivariate analyses revealed that KDM6A mutations were significantly associated with poor RFS (hazard ratio = 3.1 [1.4, 7.1], p = 0.007) and OS (HR = 11.5 [3.6, 37.0], p < 0.001); FLT3-TKD mutations, poor OS (HR = 4.9 [1.7, 14.3], p = 0.004); KIT mutation VAF > 25%, poor RFS (KIT

Indexed as

Core Binding Factor Alpha 2 SubunitCore Binding FactorsLeukemia, Myeloid, AcuteMutationAdolescentAdultAgedAged, 80 and overCore Binding Factor beta SubunitDisease-Free SurvivalFemalefms-Like Tyrosine Kinase 3Histone DemethylasesHumansMaleMiddle AgedCore Binding Factor Alpha 2 SubunitCore Binding Factor beta SubunitCore Binding Factorsfms-Like Tyrosine Kinase 3Histone DemethylasesKDM6A protein, humanMYH11 protein, humanMyosin Heavy ChainsOncogene Proteins, FusionRUNX1 protein, humanRUNX1T1 protein, humanRUNX1 Translocation Partner 1 ProteinAcute myeloid leukemiaCore binding factorGenomicSurvival prognosis

Identifiers

PMID39966122
PMCPMC11971224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.